140 related articles for article (PubMed ID: 25921217)
1. Exploring the molecular basis of action of ring D aromatic steroidal antiestrogens.
Alvarez LD; Veleiro AS; Burton G
Proteins; 2015 Jul; 83(7):1297-306. PubMed ID: 25921217
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of salpichrolide analogs as antiestrogenic agents.
Sonego JM; Rivero EM; Gargiulo L; Lüthy I; Alvarez LD; Veleiro AS; Burton G
Eur J Med Chem; 2014 Jul; 82():233-41. PubMed ID: 24908652
[TBL] [Abstract][Full Text] [Related]
3. Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics.
Celik L; Lund JD; Schiøtt B
Biochemistry; 2007 Feb; 46(7):1743-58. PubMed ID: 17249692
[TBL] [Abstract][Full Text] [Related]
4. Elucidating Binding Sites and Affinities of ERα Agonists and Antagonists to Human Alpha-Fetoprotein by In Silico Modeling and Point Mutagenesis.
Moldogazieva NT; Ostroverkhova DS; Kuzmich NN; Kadochnikov VV; Terentiev AA; Porozov YB
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019136
[TBL] [Abstract][Full Text] [Related]
5. Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain.
Sharma A; Toy W; Guillen VS; Sharma N; Min J; Carlson KE; Mayne CG; Lin S; Sabio M; Greene G; Katzenellenbogen BS; Chandarlapaty S; Katzenellenbogen JA
ACS Chem Biol; 2018 Dec; 13(12):3374-3384. PubMed ID: 30404440
[TBL] [Abstract][Full Text] [Related]
6. Ligand unbinding from the estrogen receptor: a computational study of pathways and ligand specificity.
Burendahl S; Danciulescu C; Nilsson L
Proteins; 2009 Dec; 77(4):842-56. PubMed ID: 19626711
[TBL] [Abstract][Full Text] [Related]
7. Estrogenic activity of bis(4-hydroxyphenyl)methanes with cyclic hydrophobic structure.
Kojima T; Ogawa T; Kitao S; Sato M; Oda A; Ohta K; Endo Y
Bioorg Med Chem; 2015 Nov; 23(21):6900-11. PubMed ID: 26462053
[TBL] [Abstract][Full Text] [Related]
8. Three- and four-body corrected fragment molecular orbital calculations with a novel subdividing fragmentation method applicable to structure-based drug design.
Watanabe C; Fukuzawa K; Okiyama Y; Tsukamoto T; Kato A; Tanaka S; Mochizuki Y; Nakano T
J Mol Graph Model; 2013 Apr; 41():31-42. PubMed ID: 23467020
[TBL] [Abstract][Full Text] [Related]
9. From ligand structure to biological activity: modified estratrienes and their estrogenic and antiestrogenic effects in MCF-7 cells.
Brooks SC; Skafar DF
Steroids; 2004 Jun; 69(6):401-18. PubMed ID: 15219790
[TBL] [Abstract][Full Text] [Related]
10. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha.
Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y
J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373
[TBL] [Abstract][Full Text] [Related]
11. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
[TBL] [Abstract][Full Text] [Related]
12. Computational insights into the mechanism of ligand unbinding and selectivity of estrogen receptors.
Shen J; Li W; Liu G; Tang Y; Jiang H
J Phys Chem B; 2009 Jul; 113(30):10436-44. PubMed ID: 19583238
[TBL] [Abstract][Full Text] [Related]
13. Structural insight into the antagonistic action of diarylheptanoid on human estrogen receptor alpha.
Geetha Rani Y; Lakshmi BS
J Biomol Struct Dyn; 2019 Mar; 37(5):1189-1203. PubMed ID: 29557271
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Halleux C; Kallen J; Keller H; Schlaeppi JM; Stark W
J Med Chem; 2003 Jul; 46(14):2945-57. PubMed ID: 12825935
[TBL] [Abstract][Full Text] [Related]
15. Deciphering the GPER/GPR30-agonist and antagonists interactions using molecular modeling studies, molecular dynamics, and docking simulations.
Méndez-Luna D; Martínez-Archundia M; Maroun RC; Ceballos-Reyes G; Fragoso-Vázquez MJ; González-Juárez DE; Correa-Basurto J
J Biomol Struct Dyn; 2015; 33(10):2161-72. PubMed ID: 25587872
[TBL] [Abstract][Full Text] [Related]
16. Activation helix orientation of the estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations.
Fratev F
Phys Chem Chem Phys; 2015 May; 17(20):13403-20. PubMed ID: 25927714
[TBL] [Abstract][Full Text] [Related]
17. Insights into ligand selectivity in estrogen receptor isoforms: molecular dynamics simulations and binding free energy calculations.
Zeng J; Li W; Zhao Y; Liu G; Tang Y; Jiang H
J Phys Chem B; 2008 Mar; 112(9):2719-26. PubMed ID: 18266357
[TBL] [Abstract][Full Text] [Related]
18. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site.
Anstead GM; Carlson KE; Katzenellenbogen JA
Steroids; 1997 Mar; 62(3):268-303. PubMed ID: 9071738
[TBL] [Abstract][Full Text] [Related]
19. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
20. Constructing an atomic-resolution model of human P2X7 receptor followed by pharmacophore modeling to identify potential inhibitors.
Ahmadi M; Nowroozi A; Shahlaei M
J Mol Graph Model; 2015 Sep; 61():243-61. PubMed ID: 26298810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
